Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk: A systematic review and meta-analysis.

Abstract

Objective:This meta-analysis aims to examine whether the MspI and Ile462Val polymorphisms of cytochrome P450 1A1 (CYP1A1) are associated with cervical cancer risk.Methods:Eligible case–control studies were identified dated until July 2017. Pooled odds ratios (ORs) were used to assess the strength of the association between the two variants and cervical cancer risk.Results:Thirteen studies were eligible (2148 cases and 2252 controls) concerning MspI polymorphism and 8 studies were eligible (1466 cases and 1690 controls) for Ile462Val polymorphism. MspI polymorphism seemed to result in cervical cancer risk in any genetic model (C allele vs T allele: OR = 1.44, 95% confidence interval [CI] = 1.16–1.79; heterozygous model: OR = 1.40, 95% CI = 1.08–1.82; homozygous model: OR = 2.22, 95% CI = 1.48–3.33, dominant model: OR = 1.50, 95% CI = 1.14–1.98 and recessive model: OR = 1.80, 95% CI = 1.35–2.41); similar significantly increased risk was found among Caucasians and Asians. Ile462Val polymorphism was associated with elevated cervical cancer risk (Val allele vs Ile allele: OR = 1.85, 95% CI = 1.27–2.67; heterozygous model: OR = 1.42, 95% CI = 1.28–1.61; homozygous model: OR = 2.94, 95% CI = 1.15–7.54; dominant model: OR = 2.00, 95% CI = 1.33–3.00); this finding was replicated upon Caucasian population.Conclusion:This meta-analysis demonstrated that polymorphisms in MspI and Ile462Val of CYP1A1 were risk factors for developing cervical cancer.